The commercial pipeline of recombinant antibody therapeutics is robust and 
dynamic. As of early December 2014, a total of 6 such products (vedolizumab, 
siltuximab, ramucirumab, pembrolizumab, nivolumab, blinatumomab) were granted 
first marketing approvals in 2014. As discussed in this perspective on 
antibodies in late-stage development, the outlook for additional approvals, 
potentially still in 2014 and certainly in 2015, is excellent as marketing 
applications for 7 antibody therapeutics (secukinumab, evolocumab, mepolizumab, 
dinutuximab, nivolumab, blinatumomab, necitumumab) are undergoing a first 
regulatory review in the EU or US. Of the 39 novel mAbs currently in Phase 3 
studies, a marketing application for one (alirocumab) may be submitted in late 
2014, and marketing application submissions for at least 4 (reslizumab, 
ixekizumab, ocrelizumab, obiltoxaximab) are expected in 2015. Other 'antibodies 
to watch' are those in Phase 3 studies with estimated primary completion dates 
in late 2014 or 2015, which includes 13 for non-cancer indications (brodalumab, 
bimagrumab, bococizumab, MABp1, gevokizumab, dupilumab, sirukumab, sarilumab, 
tildrakizumab, guselkumab, epratuzumab, combination of actoxumab + bezlotoxumab, 
romosozumab) and 2 (racotumomab and clivatuzumab tetraxetan) undergoing 
evaluation as treatments for cancer. In addition to the novel antibody 
therapeutics mentioned, biosimilar infliximab and biosimilar trastuzumab are 
'antibodies to watch' in 2015 because of their potential for entry into the US 
market and regulatory review, respectively.